Evogene Ltd. (EVGN)
NASDAQ: EVGN · Real-Time Price · USD
1.223
+0.018 (1.49%)
Sep 18, 2025, 4:00 PM EDT - Market closed

Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of $10.43 million. The enterprise value is $17.38 million.

Market Cap10.43M
Enterprise Value 17.38M

Important Dates

The last earnings date was Tuesday, August 19, 2025, before market open.

Earnings Date Aug 19, 2025
Ex-Dividend Date n/a

Share Statistics

Evogene has 8.71 million shares outstanding. The number of shares has increased by 32.58% in one year.

Current Share Class 8.71M
Shares Outstanding 8.71M
Shares Change (YoY) +32.58%
Shares Change (QoQ) +6.29%
Owned by Insiders (%) 0.99%
Owned by Institutions (%) 1.86%
Float 8.63M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.10
Forward PS 1.73
PB Ratio 0.84
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.84
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.21.

Current Ratio 1.89
Quick Ratio 0.89
Debt / Equity 0.21
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -20.82

Financial Efficiency

Return on equity (ROE) is -98.38% and return on invested capital (ROIC) is -67.87%.

Return on Equity (ROE) -98.38%
Return on Assets (ROA) -32.43%
Return on Invested Capital (ROIC) -67.87%
Return on Capital Employed (ROCE) -103.72%
Revenue Per Employee $80,718
Profits Per Employee -$121,821
Employee Count117
Asset Turnover 0.25
Inventory Turnover 2.68

Taxes

In the past 12 months, Evogene has paid $9,000 in taxes.

Income Tax 9,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -56.94% in the last 52 weeks. The beta is 1.29, so Evogene's price volatility has been higher than the market average.

Beta (5Y) 1.29
52-Week Price Change -56.94%
50-Day Moving Average 1.27
200-Day Moving Average 1.35
Relative Strength Index (RSI) 46.50
Average Volume (20 Days) 46,500

Short Selling Information

Short Interest 107,427
Short Previous Month 156,489
Short % of Shares Out 1.23%
Short % of Float n/a
Short Ratio (days to cover) 1.49

Income Statement

In the last 12 months, Evogene had revenue of $9.44 million and -$14.25 million in losses. Loss per share was -$2.14.

Revenue9.44M
Gross Profit 5.75M
Operating Income -19.43M
Pretax Income -21.46M
Net Income -14.25M
EBITDA -17.85M
EBIT -19.43M
Loss Per Share -$2.14
Full Income Statement

Balance Sheet

The company has $11.69 million in cash and $2.66 million in debt, giving a net cash position of $9.03 million or $1.04 per share.

Cash & Cash Equivalents 11.69M
Total Debt 2.66M
Net Cash 9.03M
Net Cash Per Share $1.04
Equity (Book Value) 12.38M
Book Value Per Share -0.41
Working Capital 13.45M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$17.62 million and capital expenditures -$583,000, giving a free cash flow of -$18.20 million.

Operating Cash Flow -17.62M
Capital Expenditures -583,000
Free Cash Flow -18.20M
FCF Per Share -$2.09
Full Cash Flow Statement

Margins

Gross margin is 60.93%, with operating and profit margins of -205.72% and -150.92%.

Gross Margin 60.93%
Operating Margin -205.72%
Pretax Margin -168.21%
Profit Margin -150.92%
EBITDA Margin -189.03%
EBIT Margin -205.72%
FCF Margin n/a

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -32.58%
Shareholder Yield n/a
Earnings Yield -136.63%
FCF Yield -174.47%

Analyst Forecast

The average price target for Evogene is $3.50, which is 186.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target $3.50
Price Target Difference 186.18%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on July 25, 2024. It was a reverse split with a ratio of 1:10.

Last Split Date Jul 25, 2024
Split Type Reverse
Split Ratio 1:10

Scores

Evogene has an Altman Z-Score of -12.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -12.37
Piotroski F-Score 2